Four Ancorato Strategies Now Available on Nitrogen Riskalyze
Ancorato's flagship strategy, Fixed-Income Structured Notes (FISN), received a Riskalyze Score of 34 and a GPA of 4.1, based on the most recent
Compared with traditional income strategies that carry similar Riskalyze Scores in the 30–40 range, FISN offers meaningfully higher income potential, lower duration exposure and a differentiated return profile. While conventional income funds rely on credit and interest-rate risk, FISN's outcomes are shaped by diversified structured notes with barrier protections, limited rate sensitivity and historically lower drawdowns. This positioning allows advisors to access a higher-income solution without increasing portfolio risk, making FISN a compelling alternative or complement to standard fixed-income allocations.
"We're excited to bring full Nitrogen visibility to our strategies," said
About Ancorato
Ancorato is a third-party money manager specializing in objective-oriented, actively managed structured note SMAs. The firm combines institutional-level due diligence, risk-focused strategy design, and weekly active management to help financial advisors implement structured note solutions efficiently and transparently. Ancorato's mission is to simplify structured investments for advisors and their clients.
For more information, visit AncoratoCapital.com.
The foregoing information is for educational purposes only and not an offer to sell a particular product or service. Further, the foregoing information is not to be relied upon as personalized investment advice. Past performance is no guarantee of future results.
Contact:
Spotlight Marketing Communications
949.427.1462
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/four-ancorato-strategies-now-available-on-nitrogen-riskalyze-302643715.html
SOURCE Ancorato
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rhode Island Gets Its Own Nuvia Dental Implant Center Opening August 19 in Johnston
- Insight Global Invests More Than $100 Million in Employee Training and Development Programs
- Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share